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ABSTRACT
Introduction: Colorectal cancer is the third most common cancer in the world, a 
small fraction of which is represented by locally advanced rectal cancer (LARC). If not 
medically contraindicated, preoperative chemoradiotherapy, represent the standard 
of care for LARC patients. Unfortunately, patients shows a wide range of response 
rates in which approximately 20% has a complete pathological response, whereas in 
20 to 40% the response is poor or absent.
Results: The following specific gene signature, able to discriminate responders’ 
patients from non-responders, were founded: AKR1C3, CXCL11, CXCL10, IDO1, CXCL9, 
MMP12 and HLA-DRA. These genes are mainly involved in immune system pathways 
and interact with drugs traditionally used in the adjuvant treatment of rectal cancer.
Discussion: The present study suggests that new ideas for therapy could be found 
not only limited to studying genes differentially expressed between the two groups 
of patients but deepening the mechanisms, associated to response, in which they are 
involved.
Methods: Gene expression studies performed by: Agostini et al., Rimkus et al. 
and Kim et al. have been merged through a meta-analysis of the raw data. Gene 
expression data-sets have been processed using A-MADMAN. Common differentially 
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expressed gene (DEG) were identified through SAM analysis. To further characterize 
the identified DEG we deeply investigated its biological role using an integrative 
computational biology approach.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer in the world. According to recent epidemiological 
data, in 2014 nearly 50,310 patients died from CRC with 
a substantial equality distributed in both sex [1]. One-third 
of CRC are represented by rectal cancer (RC) and 40% of 
this are locally advanced rectal cancer (LARC). Although 
the genetic screening has been proven to greatly reduce 
the mortality for CRC, up to now there is a deficiency 
of clinical tools for an effective and early individuations 
of neoplasia. Preoperative chemoradiotherapy (pCRT), 
presently the standard of care for LARC [2–6], shows 
unfortunately a wide range of response rates in which 
approximately 20% of patients have a complete 
pathological response, whereas in 20 to 40% of patients 
the response is poor or absent [7, 8]. In addition, an 
ineffective pCRT is time-consuming, expensive and 
increases the perioperative morbidity. The development 
of novel approaches predictors of tumor response to 
pCRT are critical in reducing mortality in LARC and 
in sparing poorly responding patients from unnecessary 
treatments. Several studies have been performed to 
evaluate potential predictors of response after pCRT 
in rectal cancer, however the data are still unclear and 
controversial [9, 10]. Discrepancies among studies were 
mainly related to patient selection, sample size, study 
design, treatments and parameters used for tumor response 
evaluation. As a consequence, the only accepted marker 
to monitor colorectal cancer treatment, progression and 
disease relapse is the carcinoembryonic antigen (CEA), 
but its sensitivity and specificity, especially for early stage 
colorectal cancer, seems to be insufficient [10, 11]. Drug 
sensitivity in chemotherapy is thought to be attributable 
to the variations in the genetic background of cancer cells 
and gene expression signatures have a great potential for 
predicting therapeutic outcomes better than conventional 
clinical and pathological approaches [12]. In this 
landscape, gene signatures, based on rectal cancer cell 
expression profiling obtained by microarray technology, 
could be useful predictors of tumour response after pCRT. 
Some studies focusing on the prediction of response to 
treatment based on mRNA gene expression in LARC 
patients have been performed, but no overlap was found 
in the predictive genes list [12, 13] since the analyzed 
patients had received heterogeneous treatments.
For instance, in the paper from Watanabe et al. [14] 
patients were treated with radiotherapy alone, whereas 
Cetuximab was added to the conventional pCRT by Daemen 
et al. [15] and Debucquoy et al. [16]. In other studies 
[17–19] and a paper from our laboratory [20] the major 
limitation is probably the number of patients tested.
The “meta-analysis” of data produced by different 
but comparable studies could in theory increase the 
statistical power and reliability of the study beyond the 
original experimental design. On the other hand, different 
datasets are often produced using different platforms, 
presenting some challenges for meaningful data integration 
[21]. In this scenario there are two main possible strategies 
to integrate the results of independent gene expression 
studies: i) the combination of retrospective analysis 
results (i.e. final lists of differentially expressed genes); 
ii) de-novo analysis (re-analysis) of raw data [22, 23].
In this study, we performed a de novo meta-analysis 
on data from rectal tumor tissue to identify a gene set 
associated to pCRT response in association with the disease 
free survival data. The Annotation-based Microarray Data 
Meta-ANalysis tool (A-MADMAN; http://compgen.bio.
unipd.it/bioinfo/amadman/) [24], an open source web 
application that was already successfully used in several 
studies [25–27] was used to retrieve, annotate and integrate 
gene expression data from three independent datasets.
In addition, we applied an integrated computational 
approach to interpolate data derived from genetic 
signatures and proteomic analyses to achieve more reliable 
predictions in the response to treatment.
RESULTS
Responders vs non-responders: meta-analysis of 
clinical and gene expression data
Initially, we focused on clinical data to understand 
whether there was a correlation between responses to 
therapy with the overall survival. Then, we integrated gene 
expression signatures with both functional information, such 
as: biological processes (BP), cellular components (CC) and 
molecular functions (MF); and clinical data to search for 
differences in gene expression linked to pCRT response and 
to obtain information on the molecular mechanisms that 
could be involved in differential survival.
The array-based gene expression profiling in LARC 
tumor samples in relation to pCRT response of patients 
has been evaluated in a cohort of 85 samples, coming from 
the three independent studies. Data have been collected 
and integrated to conduct a meta-analysis aiming at the 
identification of a robust gene signature able to predict 
chemo-radio resistance.
In this regard, we compared the gene lists identified 
by the three independent studies. No shared markers 
resulted after data intersection, including XRCC3 the 
promising gene identified in our study, probably due to 
the different data analysis procedures (Supplemental 
Table 1). To address this issue, we processed together the 
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raw data retrieved by the three studies to obtain a larger 
statistical sample. Through a de-novo integration of gene 
expression data in a single matrix we selected 277 genes 
with an expression profiles significantly deregulated, while 
low expression variation have been filtered out using the 
interquartile range (IQR) criteria (Supplemental Table 2).
A signature of chemoradio resistance in LARC
SAM analysis was performed on 277 significantly 
expressed genes between responders (R) and non-
responders (NR) groups. Through this method, we found 
a specific gene signature able to discriminate R from NR: 
one gene was significantly under-expressed (AKR1C3 
[Gene ID: 8644]), while six genes were over-expressed 
(CXCL11[Gene ID: 6373], CXCL10[Gene ID: 3627], 
IDO1[Gene ID: 3620], CXCL9[Gene ID: 4283], 
MMP12[Gene ID: 4321] and HLA-DRA[Gene ID: 3122]) 
in responders group with FDR < 1% and q-value = 0 
(Table 1). The SAM plot with significantly up- and down-
regulated genes, the heatmap of Differentially Expressed 
Genes (DEG) expression profiles and the boxplot showing 
expression variation of DEGs in considered groups are 
reported in (Supplemental Figure 1).
Gene ontology (GO) analysis has been performed 
on the seven selected genes. DAVID web-based tool was 
used to investigate biological processes (BP), cellular 
components (CC) and molecular functions (MF) shared 
by them. Ordered by statistical significance, BP results 
showed that five out of seven genes (CXCL10, CXCL11, 
CXCL9, IDO1, HLA-DRA) were involved in defense 
response and four genes (CXCL10, CXCL11, CXCL9, 
IDO1) in inflammatory response pathway. Four genes 
(CXCL10, CXCL11, CXCL9, MMP12) encoded for 
proteins commonly located in the extra-cellular regions, 
according to CC information. Three genes (CXCL10, 
CXCL11, CXCL9) showed the same MF sharing 
chemokine, cytokine activity and chemokine receptor 
binding. The most significant three out of seven SAM 
genes (AKR1C3, CXCL10 and IDO1, Figure 1) were 
Table 1: SAM results, genes deregulated in Responders (R) group. 
Probe ID Gene Symbol Expression meanNR mean R Description
GC10P005126_at AKR1C3Gene ID: 8644 ↓R 8.818 7.766
Encodes a member of the aldo/keto 
reductase superfamily. It catalyzes the 
conversion of aldehydes and ketones to 
alcohols.
GC04M077145_at CXCL11 Gene ID: 6373 ↑R 3.787 4.875
Is a CXC member of the chemokine 
superfamily. Chemotactic for interleukin-
activated T-cells but not unstimulated 
T-cells, neutrophils or monocytes, ligand 
for the receptor CXCR3.
GC04M077132_at CXCL10 Gene ID: 3627 ↑R 6.693 7.680
Encodes a chemokine of the CXC 
subfamily and ligand for the receptor 
CXCR3.
GC08P039891_at IDO1Gene ID: 3620 ↑R 6.095 7.007
Encodes a heme enzyme that catalyzes the 
first and rate-limiting step in tryptophan 
catabolism to N-formyl-kynurenine, 
immune-modulatory properties.
GC04M077112_at CXCL9 Gene ID: 4283 ↑R 6.130 7.064
The function has not been specifically 
defined; however, it is thought to be 
involved in T cell trafficking, ligand for the 
receptor CXCR3
GC11M102238_at MMP12 Gene ID: 4321 ↑R 8.819 9.580
Encodes a protein of the matrix 
metalloproteinase (MMP) involved in the 
breakdown of extracellular matrix.
GC06P032434_at HLA-DRA Gene ID: 3122 ↑R 7.759 8.430
Encodes a protein that binds peptides 
derived from antigens that access the 
endocytic route of antigen presenting cells 
(APC) and presents them on the cell surface 
for recognition by the CD4 T-cells.
Only genes with FDR < 1% and q-value = 0 are listed
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further validated by the multtest Benjamini–Hochberg 
procedure with p = 0.05 assumption.
We also estimated the prediction error via cross-
validation using PAM machine learning method, which 
provides a list of significant genes able to discriminate 
between responders and non-responders.
No genes were found (PAM, Supplemental Figure 2) 
to be predictive in distinguishing responders from non-
responders groups. A comprehensive summary (Table 2) 
was created to summarize the analyses results.
To further strengthen our results, we validated the 
predictive power of genetic signature by an elaboration 
of data from two independent TCGA CRC cohorts, 
respectively (n = 237) and (n = 881); in two out seven DEG, 
one over-expressed and one under-expressed. This result, 
in complete accordance with our data, showed an over-
expression of IDO1 and an under-expression of AKR1C3 
in responders patients (Supplemental figure 3) according 
to Residual tumor classification (see Methods paragraph), 
confirming the same trend obtained in our study [28].
Multivariate analysis
We have considered a multivariate linear model 
to relate AKR1C3, CXCL10 and IDO1 to the variables 
with 100% of values available for each paper (Batch, 
Age, Sex, pT, LN, Metastases and Response). Multiplicity 
corrections have been performed using Holm-Bonferroni 
method to control the family wise error rate. A test 
was deemed significant if the corresponding adjusted 
p-value was below 0.05. We found that AKR1C3 
showed a statistical significant decrease if the observations 
belong to pT(1) (estimate -1.928e+09, corrected 
p = 0.029440572) and a significant increase if the 
observations belong to Response(2) (estimate 1.309e+09, 
corrected p = 0.006074293).
Genes correlated with survival
We further evaluated the entire gene expression 
profiles for two out of three studies to identify genes 
related to survival (Agostini et al.; Rimkus et al.). Four 
and seven genes were found to be significantly associated 
with death event using respectively local false discovery 
rate (lFDR < 0.05) and q-value (qval < 0.05) methods 
(Supplemental Figures 4a and 4b). Over-expression of 
INPP1[Gene ID: 3628], CYB5D1[Gene ID: 124637], 
KDELR3[Gene ID: 11015] and down-regulation of 
SLC26A2[Gene ID: 1836], VPS13C[Gene ID: 54832], 
PRKCQ[Gene ID: 5588] and TRIM2[Gene ID: 23321] 
genes characterized the event-related group.
From genes and response mechanisms to new 
ideas for therapy?
We utilized a systems biology approach to gain at 
least preliminary hypotheses of the mechanisms that could 
be involved in differential patients’ response to therapy. 
The network analysis performed on AKR1C3, CXCL10 
and IDO1 showed that these three genes are not directly 
connected but participate in a network of 33 genes with 
80 interactions (Figure 2). The pathway analysis of the 
entire network reveals that the immune system pathway is 
enriched (p = 3.64E-07) and involves the most part of the 
central nodes in the network connecting the three genes 
(Supplememtal table 3).
Figure 1: Three genes were validated using Multtest package (Benjamini–Hochberg procedure with p = 0.05 
assumption). As shown by the heatmap of gene expression profiles in considered samples (left) and by the Boxplot (right), IDO1 and 
CXCL10 genes are up-regulated in Responders group, while AKR1C3 is down-regulated.
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We then used “The Comparative Toxicogenomics 
Database” CTD, to highlight which known chemical 
compound targets the genes of the previously built 
network (Figure 3, panel a). Benzo(a)pyrene, quercetin 
and nickel sulfate are the only ones targeting all three 
signature genes. Drugs traditionally used in the adjuvant 
treatment of rectal cancer were reported in the network 
dependencies: capecitabine, 5-fluorouracil (both targeting 
AKR1C3), irinotecan and oxaliplatin (Figure 3 panel b) 
and (Supplemental table 4).
The network analysis of the survival genes has also 
been performed. A network of 69 nodes with 157 edges 
showed that the immune system pathway as the most 
enriched one (p value = 6.13E-22) (Figure 4).
DISCUSSION
Clinically, preoperative chemoradiotherapy, is 
the worldwide standard regime for locally advanced 
rectal cancer. However, the therapy outcome is very 
heterogeneous, and ineffective therapy is time-consuming, 
economically ineffective, and leads to increased morbidity. 
Therefore, reliable prediction of therapy response by 
novel approaches is urgently awaited. In the past, gene 
Table 2: Summary table for statistical tests performed to find differentially expressed genes 
between responders and non-responders groups on 85 samples.
Gene Expression SAM PAM Multtest ST - lFDR ST - qval
AKR1C3 ↓R passed failed passed failed failed
CXCL11 ↑R passed failed failed failed failed
CXCL10 ↑R passed failed passed failed failed
IDO1 ↑R passed failed passed failed failed
CXCL9 ↑R passed failed failed failed failed
MMP12 ↑R passed failed failed failed failed
HLA-DRA ↑R passed failed failed failed failed
Figure 2: Network analysis of the three genes response-related signature positive to the multtest. Squares indicate the 
signature genes, red outline highlights genes involved in the immune system pathway. Node colors are related to Gene Ontology terms as 
shown in the legend.
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Figure 3: A. Known chemical compounds targeting the signature network reported in Figure 2. Labeled compounds are 
the only ones targeting all three-signature proteins. Blue edges show protein-protein interactions, red edges connections between the labeled 
compounds and their direct targets. B. Drugs network summary. In black are reported drugs and chemical compounds. The drugs used in 
rectal cancer treatment and their targets are shown. Highlighted in red are compounds that are known to be related to CRC carcinogenesis. 
Light gray edges show interactions between signature genes and drugs targeting all of them.
Figure 4: Survival signature network. Survival genes are diamond-shape nodes, while highlighted nodes are part of the Immune 
system pathway. Node colors are related to Gene Ontology terms as shown in the legend. Green edges are shortest paths between survival 
genes.
Oncotarget32567www.impactjournals.com/oncotarget
expression profiling has been used to define biomarkers 
for tumor response to pCRT by several groups. However, 
single-center studies rely on relatively low case numbers, 
leading to very limited levels of overlap between the 
findings, as our own results demonstrate for three recent 
studies (Supplemental Table 1). Therefore, we have chosen 
here a new approach based on de novo bioinformatics 
analysis of the original data, a powerful strategy for 
the generation of new potential biomarkers for therapy 
response stratification.
Firstly, an interesting things approaching to 
this manuscript is that none of our predictive genes 
are consistent with other comparable studies before 
mentioned. This apparent discrepancy in results, is mainly 
due to the high heterogeneity in a series of parameters 
including: number of patients enrolled, studies design 
and methods, primary end-point, treatment’s protocol, 
criteria used for evaluation of treatment response, 
microarray platform and statistic tools. For example, 
Debucquoy et al. while using our similar approach, treat 
LARC patients with a primary end-point of evaluating the 
efficacy of a COX-2 inhibitor combined with canonical 
chemoradiotherapy. Instead, Ghadimi et al. used both a 
different therapeutic treatment protocol and responders/
non-responders evaluation method with our same primary 
scope. Conversely, Watanabe et al. and Brettingham-
Moore et al. studies is the most comparable works in term 
of study design and practical approach. Watanabe et al. 
enrolled fifty-two rectal patients who underwent pCRT and 
through microarray genes expression profile identified a 
signature of 33 differently expressed genes discriminating 
responders from non-responders patients. The list of 
discriminating genes included growth factor, apoptosis, 
cell proliferation, signal transduction, or cell adhesion–
related genes but none are in common with our findings. 
Brettingham-Moore et al. highlight how the result 
obtained with microarray approach fail to reach a sufficient 
sensitivity and specificity in stratifying responders from 
non-responders patients, with a poor predictive power, 
reproducibility and a high rate of false-positive. However, 
using an alternative computational approach they found 
that a particular biological pathway was principally 
involved and high correlated to patient’s response to 
treatment: the TNF/NF-kB pathway. Consistently with 
our result they found that inflammation, especially which 
involved in tumor microenvironment, often cooperate with 
a complex network of signals determining sensitivity to 
chemoradiotherapy.
Secondly, the results here presented support the 
growing evidence of tumor microenvironment (TME) 
involvement in neoplastic progression [29]. While some 
aspects of TME are now well characterized such as tumor 
angiogenesis sustaining and reshaping of extracellular 
matrix, the impact of TME on tumor grown, progression 
and response to therapy is still not fully clarified. In this 
landscape, the intersection between tumor and immune 
system is increasingly taking on the characteristics of a 
double-edge sword. In particular the Infiltrating Immune 
Cells (IIC) seems to, directly and indirectly, supply a series 
of mediators able to sustain tumor unchecked proliferation 
and to interfere with prognosis and treatment response.
In the present de novo meta-analysis study, we found 
three genes: CXCL10, IDO1 and AKR1C3 associated to 
chemo-resistance in rectal cancer patients. These genes 
showed a common involvement in the immune system 
pathway by performing network analysis. The same 
result was obtained for the genes associated to survival. 
The adaptive immune system has been described to be 
involved in colorectal carcinogenesis and it has been 
already correlated to survival [30].
Of note, the three chemokines CXCL11, CXCL10, 
and CXCL9 were all found to be upregulated in therapy 
responders. These interferon-regulated CXC-family 
cytokines all bind to the same receptor, CXCR3[Gene 
ID: 2833], which is expressed on TH1-type T-cells and 
endothelial cells [31]. These cytokines, most prominently 
CXCL10 (IP-10), are involved in chemotaxis of monocyte 
and anti-tumoral TH1-type T-lymphocytes, in the regulation 
of cell growth and have been described to inhibit 
angiostasis. For cell-mediated immunity, CXCL10 exerts 
a powerful thymus-dependent antitumor effect [32] and 
several studies have established a prominent role for NK 
cells in CXCL10-mediated antitumor activity [33].
Therefore, a deregulation of chemokine modulation 
in leukocyte recruitment might favour cancer promotion. 
For example, impaired production of CXCL10 might be 
the basis of decreased immune responses at sites of chronic 
inflammation that lead to neoplastic transformation [34] 
and more aggressive phenotypes. Low expression of 
CXCL10 has been previously associated with survival in 
stage II and III colorectal cancers and it could be used 
as a marker to better characterize high risk patients and 
maximize the benefits of adjuvant therapy [35]. Moreover, 
high CXCL10 mRNA expression is associated with a 
better tumor response to pCRT in LARC patients and may 
predict the outcome of pCRT in this malignancy [36]. It is 
noteworthy that the immune system was described as the 
main player in more than one part of this study. It is now 
well known that a chronically inflamed microenvironment, 
immune escape and immunosuppression are mechanisms 
intertwined with cancer development, to the point of 
being recognized as “immune hallmarks of cancer” [37]. 
Our results highlight the importance of a correct immune 
response in rectal cancer, and confirm the role of immune 
related pathways in modeling different responses to the 
same treatment [38]. Consistently with our results, the 
study of Zumwalt et al. [39] revealed that transcriptional 
expression and secretion of CXCR3 and CCR5, cognate 
chemokines, correlate with CD8+ T-cell infiltration 
and prolonged survival in colorectal cancer. Similarly, 
Sconocchia et al. [40] assessed that NK cell and CD8+ 
T cell crosstalk in the tumor microenvironment may 
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benefit patient outcome and further, that the enumeration 
of infiltrating NK and CD8+ T cells in CRC tumors may 
provide useful prognostic information.
The importance of CXCL10 and CXCL9 in the 
generation of an efficient antitumor immune response is 
further supported by their prominent role as mediators of 
the antitumor effect of IL-12[Gene ID: 3593], which is 
known as a potent immunoregulatory cytokine mediating 
tumor regression in a variety of tumor models [33, 41].
IDO1 is a fundamental enzyme in the tryptophan 
catabolism pathway and the data available in literature 
appear conflicting. A study on IDO1 expression in 
primary colorectal tumours demonstrated that higher 
IDO1 expression at the tumour invasion front correlates 
with progressive disease and impaired clinical outcome. At 
stage-III colorectal cancer patients, decisions for adjuvant 
treatment are weighed against possible side effects in 
patients with important comorbidity and the analysis 
of IDO1 expression at the tumour invasion front was 
suggested to be of additional value in the decision process 
[42]. Moreover, IDO1 has been demonstrated to promote 
colitis-associated tumorigenesis in mice, independent of 
its ability to limit T-cell–mediated immune surveillance. In 
the mechanism proposed, IDO1 regulates the suppression 
of tumor-reactive effector T cells and promotes the 
regulation of T cell activation limiting tumor immune-
surveillance and thus facilitating tumor progression. 
Concurrently, it stimulates proliferation in the neoplastic 
epithelium through activated nuclear b-catenin [43].
AKR1C3 is an aldo–keto reductase that has been 
described as responsible for gaining resistance against 
cisplatin treatment when overexpressed in colon cancer 
cells together with AKR1C1[Gene ID: 1645] [44].
AKR1 family genes (C1 and C3) are potential 
markers for cisplatin resistance of colon cancer cells. 
In response to oxidative stress including ROS and 
electrophiles, Nrf2 is released from the Nrf2–Kelch-like 
ECH-associated protein 1 (Keap1 [Gene ID: 9817]) 
complex by modification of Cys in Keap1. Nrf2 translocates 
into the nucleus to binds antioxidant response elements, 
inducing a variety of phase II enzymes involved in drug 
metabolism, such as NAD(P)H quinone oxidoreductase-1, 
heme oxygenase-1 and the AKRs (1C1, 1C2, 1C3 and 
1B10) [45, 46].
Since cisplatin induces oxidative stress, it has 
been suggested that the over-expression of AKR1C1 and 
AKR1C3 in cisplatin resistance cells results induced from 
Nrf2 activation through continuous formation of ROS and 
HNE. The positive relationship between the up-regulation 
of the two AKRs and the development of cisplatin 
resistance, seems to indicate that high expression of AKR1 
genes (C1 and C3) is a crucial factor in the ineffectiveness 
of cisplatin therapy for colon cancer.
Drugs used in the adjuvant treatment of rectal cancer 
(capecitabine, fluorouracil, irinotecan and oxaliplatin) 
are present in the network connecting the three genes 
(Figure 3, panel b).
A search for compounds that target all three genes 
pointed at benzo(a)pyrene, nickel sulfate and quercetine. 
Benzo(a)pyrene has been linked to colorectal cancer 
development [47] while nickel sulfate is a known 
carcinogen [48]. On the contrary quercetin has been 
associated to colorectal cancer prevention and treatment 
of rectal and ileal adenomas [49, 50]. A further analysis 
on the interactions revealed that the two carcinogens 
induce the expression of the three genes while quercetin 
induces the expression of IDO1 but inhibits the expression 
of CXCL10 and AKR1C3. As IDO1 is up-regulated and 
AKR1C3 is down-regulated in responders, quercetin might 
be a good candidate in support to adjuvant chemotherapy 
in non-responders patients.
Interestingly, STAT1[Gene ID: 6772], NFKB1[Gene 
ID: 4790] and JUN[Gene ID: 3725] genes, three crucial 
signaling molecules in cancer cells, have been further 
identified as common targets of the three compounds. 
The enrichment of the immune system pathway was 
confirmed also considering the six genes targeted by the 
three compounds (p = 0.0228). Notably, STAT1, NFKB1 
and JUN are also targeted by irinotecan while fluorouracil 
targets NFKB1 and JUN and oxaliplatin targets JUN.
The present study furthermore, allowed the 
identification of a subclass of genes related to survival. 
Among these genes, INPP1 in particular stands out 
for which its overexpression is positively correlated to 
death-event. The over expression in colorectal cancer of 
INPP1 was primary described by Bustin and colleagues 
[51]. This gene produces an important enzyme involved 
in the Inositol signaling pathway that play a crucial role 
in cellular proliferation, differentiation and apoptosis 
[52, 53]. INPP1 belongs to a class of hydrolases acting 
specifically on position 1 phosphate of both InsP2 and 
InsP3. The production derived from its catalysis functions 
as effector molecule in favor of DNA Polymerase α, 
required for the priming of Okazaki fragments during 
elongation [54], increasing its fidelity and activity of 
replication [55]. A deregulated activity of INPP1 has also 
been demonstrated in colorectal cancer and in prostate 
cancer, where it has been proposed as therapeutic target 
[56]. In concert with our data, we speculate that an over-
activation of INPP1, besides increasing the activity and 
stability of DNA Polymerase α promotes cancer cell 
replication, stimulates the generation of some second 
messengers such as diacylglycerol and InsP3 which are 
important in the activation of protein kinase C, responsible 
for survival and propagation of proliferation-enhancing 
stimuli.
Another noteworthy gene is CYB5D1, which 
encodes for a protein belonging to the family of Hpr6, 
which was found to increase the resistance of tumor cells 
to DNA damaging agents [57]. This study is the first, up to 
now, that positively correlates overexpression of CYB5D1 
with an increased patients risk. In fact, CYB5D1 was 
already decribed in the study of breast and other cancer 
but its expression levels negatively correlates with patients 
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survival, suggesting an opposing effects, which may be 
tumor-type specific [58, 59].
With respect to down-regulated genes, SLC26A2 
alias DTD or DTDS, is an interesting gene, which 
positively correlated with death-event. This gene encodes 
for a protein responsible of sulfate transport across 
membrane. In cancer cell and especially in colorectal 
cancer cell, we assist to an impaired sulfation that occurs 
during the course of malignant transformation of colonic 
epithelium. A study proposed by Kannagi and colleagues 
demonstrated that cultured colorectal cancer cells have 
a markedly reduced expression of DTDST and the 
down expression dramatically increased growth rate and 
proliferation of cancer cells [60].
In conclusion, our study paves the way for an 
original approach in order to facing the dramatic increase 
of high throughput generated data. In fact, we must 
consider that the increasing use of high throughput assays 
shifted research from hypothesis-driven exploration to 
data-driven hypothesis generation, in this scenario an 
effective tool as A-MADMAN algorithm allow a fast, 
comprehensive and reliable statistical method to analyze 
heterogeneous data, coming from different analytical 
platforms. All these arguments suggest that new ideas 
for therapy, as well as new tools for patient stratification 
according to the individual molecular genetic risk profile 
could be found studying genes and mechanisms associated 
to therapy response.
MATERIALS AND METHODS
Gene expression datasets selection
In this study, three different gene expression 
datasets of pCRT-treated patients with LARC have been 
investigated. A total of 131 patient have been included. 
Only data belonging to original samples with > 70% of 
tumor cells and a comparable pCRT treatment protocol 
were used in our meta-analysis. Rimkus et al. [19] used 
43 biopsy specimens of LARC patients receiving a pCRT 
standardized protocol: 45 Gy, 5-fluorouracil - 250 mg/m2/
continuously followed by surgical resection six weeks 
later.
Agostini et al. (in press [20]) used tumor tissue 
obtained from 42 patients with LARC. All patients 
received pCRT using the standardized protocol as follow: 
45–50.4 Gy; 5-fluorouracil - 225 mg/m2/continuously. 
Surgical excision has been performed six weeks after 
pCRT. In the two original studies, patients showing 
tumor regression grades 1–2 and 3–4 of the Mandard 
classification [61] were classified as responders and non-
responders, respectively.
Kim et al. [18] used tumor tissues obtained from 
46 patients with LARC. All patients were treated with 
radiotherapy with 50.4 Gy, followed by surgical excision 
six weeks later. The response to chemoradiotherapy 
was evaluated according to Dworak’s tumor regression 
grade: grades 1–2 were considered non-responders, while 
grades 3–4 were considered as responders [62]. The main 
information for each study has been reported (Table 3). All 
genes ID have been retrieved from NCBI Gene database
Data retrieval, annotation, integration and 
quality control
We used A-MADMAN web application for 
retrieving, annotating, organizing and analysing gene 
expression datasets of meta-analysis, originating from 
Affymetrix data. Interestingly, A-MADMAN allows 
the integrative analysis of data obtained from different 
Affymetrix platforms through a custom workflow by 
minimizing inter-series and inter-studies variability 
biases. This is based on the Robust Multichip Average 
(RMA) method [63] implemented in the Bioconductor 
R package ‘affy’, using GeneAnnote-based custom CDF 
[64]. Oligonucleotides common to all platforms were 
selected and each array was transformed into a virtual 
chip containing only the common probes. Background 
correction was applied for each platform before the 
oligonucleotides selection, while the summarization and 
the quantile normalization by RMA were performed only 
on shared probes.
R pamr package (CRAN Comprehensive R Archive 
Network; http://cran.r-project.org) was applied after 
normalization to remove batch effects.
Three series of Affymetrix data were downloaded 
and a total of 131 patients were considered. The data were 
obtained from two different generations of Affymetrix 
gene chip technologies that were not directly comparable: 
Human Genome U133A was used by Kim et al., while 
Human Genome U133 plus2.0 GeneChip Array was used 
by Rimkus et al. and Agostini et al.
Raw data (CEL files) and related metadata were 
imported and clinical and pathological information 
Table 3: Summary table comparing the three studies used for meta-analysis.
Manuscript Study group Arrays Survival Platform
Rimkus et al., CGH 2008 Germany 15 Yes HG-U133Plus2.0
Agostini et al., (in press) Italy 40 Yes HG-U133Plus2.0
Kim et al.,DCR 2007 Korea 30 No HG-U133A
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(age, sex, ethnicity, primary tumor site, stage, tumor 
grade) were used to build a local database, as previously 
described [24]. Briefly, metadata were associated to each 
sample as descriptive labels (tags) to subset samples into 
homogenous groups.
A quality check of the expression data was applied 
using a customized version of ArrayQualityMetrics 
Bioconductor package in R statistics environment 
(BioConductor, http://www.bioconductor.org) to discard 
those samples that were marked as outliers in more 
than two Quality Control (QC) metrics. Specifically, 
two main Probe-Level Method-based quality statistics, 
such as: Normalized Unscaled Standard Error (NUSE) 
with Relative Log Expression (RLE), and a QC 
metric recommend by Affymetrix (QC stats) were 
used to evaluate the overall quality of signals in each 
array. MA-plot before and after RMA was performed 
to identify biases associated with specific intensity 
classes [65].
By the A-MADMAN web interface, all samples 
were meta-analysed to derive an integrated gene 
expression matrix.
Gene Expression Profiling
Statistical analyses were performed using the open-
source R System software [The R Project for Statistical 
Computing, ver.2.12.2, http://www.r-project.org], 
BioConductor package [ver.2.7] and dChip software, 
including 12,167 probe sets and 85 samples resulting 
from annotation, integration and QC procedures above 
described.
Genes with low expression variation across all 
samples have been discarded using interquartile range 
(IQR) as filtering criteria; as a result, subsequent analysis 
has been performed using a total of 277 filtered probe sets.
A significance analysis of microarray (SAM) has 
been performed to find differentially expressed genes 
between responders (R) and non-responders (NR) groups. 
Less than one false positive-rated gene was found using 
false discovery rate (FDR) < 1% and q-value = 0 as 
cutoffs.
Shrunken centroid algorithm was further performed 
using Tibshirani’s class prediction analysis of microarrays 
(PAM). The ‘multtest’ package was used for multiplicity 
control as described in Pollard, K. S., Gilbert, H. N., Ge, Y., 
Taylor, S. & Dudoit, S. (2011), multtest:
Resampling-based multiple hypothesis testing.
The false discovery rate (FDR) has been calculated 
by the Benjamini–Hochberg procedure and statistical 
threshold for significance was set to p = 0.05.
The functional annotation of gene lists derived from 
the above described analysis was performed by the DAVID 
(Database for Annotation, Visualization and Integrated 
Discovery) [web-tool: http://david.abcc.ncifcrf.gov/].
Survival data, available for 55 samples in two out of 
three original studies (Table 1) were considered also. We 
investigated the two databases to identify survival-related 
genes using “shrinkage t” statistics and “st” R package.
TCGA data set analysis
Data from TCGA pilot project established by the 
NCI and NHGR were explored (22nd June 2015) for 
AKR1C3 and IDO1 expression in the TCGA colorectal 
cancer series. Information about TCGA and the 
investigators and institutions that constitute the TCGA 
research network can be found at “http://cancergenome.
nih.gov”. Oncomine algorithms were used for the 
statistical analysis of the differences in AKR1C3 and 
IDO1 mRNA expression [66]. TCGA data series were 
grouped by Residual tumor, a parameter that reflects the 
effects of treatment as described by Hermanek et al. [28]. 
Briefly, R0 were considered complete/good response while 
R1 and R2 bad/absent response.
Network Analysis
The biological role of selected genes, which enable 
the discrimination of two groups, is better characterized 
through an in-depth analysis of the molecular pathways 
in which they are involved. In this regard, we utilized a 
series of tools in order to investigated different biological 
network at different level: a) protein-protein interactions 
(PPIs) and enrichment analysis; b) common microRNAs 
interactions; c) common interaction with drugs.
The selected genes were initially characterized 
by retrieving physical PPIs from “I2D database ve, 
creating a PPI network that was visualized and analyzed 
in “NAViGaTOR 2.3 [67]”. We further performed a 
functional annotation and enrichment analysis of the 
network proteins using the built in pathway plugin, a 
study of the microRNAs targeting the PPI network using 
“mirDIP 1.1” [68], and a study of the drugs targeting 
the same network using (CTD). Moreover, to prioritize 
microRNAs in the network, data from published studies 
on response to neoadjuvant chemoradiotherapy and 
microRNA signatures were collected [69–71].
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